Back to Search Start Over

FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.

Authors :
Maachani UB
Shankavaram U
Kramp T
Tofilon PJ
Camphausen K
Tandle AT
Source :
Oncotarget [Oncotarget] 2016 Nov 22; Vol. 7 (47), pp. 77365-77377.
Publication Year :
2016

Abstract

Glioblastoma multiforme (GBM) continues to be the most frequently diagnosed and lethal primary brain tumor. Adjuvant chemo-radiotherapy remains the standard of care following surgical resection. In this study, using reverse phase protein arrays (RPPAs), we assessed the biological effects of radiation on signaling pathways to identify potential radiosensitizing molecular targets. We identified subsets of proteins with clearly concordant/discordant behavior between irradiated and non-irradiated GBM cells in vitro and in vivo. Moreover, we observed high expression of Forkhead box protein M1 (FOXM1) in irradiated GBM cells both in vitro and in vivo. Recent evidence of FOXM1 as a master regulator of metastasis and its important role in maintaining neural, progenitor, and GBM stem cells, intrigued us to validate it as a radiosensitizing target. Here we show that FOXM1 inhibition radiosensitizes GBM cells by abrogating genes associated with cell cycle progression and DNA repair, suggesting its role in cellular response to radiation. Further, we demonstrate that radiation induced stimulation of FOXM1 expression is dependent on STAT3 activation. Co-immunoprecipitation and co-localization assays revealed physical interaction of FOXM1 with phosphorylated STAT3 under radiation treatment. In conclusion, we hypothesize that FOXM1 regulates radioresistance via STAT3 in GBM cells. We also, show GBM patients with high FOXM1 expression have poor prognosis. Collectively our observations might open novel opportunities for targeting FOXM1 for effective GBM therapy.

Details

Language :
English
ISSN :
1949-2553
Volume :
7
Issue :
47
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
27764801
Full Text :
https://doi.org/10.18632/oncotarget.12670